BRISTOL MYERS SQUIBB CO shareholders Q2 2023

BRISTOL MYERS SQUIBB CO's ticker is BMY and the CUSIP is 110122108. A total of 2,424 filers reported holding BRISTOL MYERS SQUIBB CO in Q2 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.

BRISTOL MYERS SQUIBB CO shareholders Q2 2023
NameSharesValueWeighting ↓
DUNCKER STREETT & CO INC 58,719$3,755,1020.84%
LVW Advisors, LLC 68,093$4,354,5590.84%
Shelter Mutual Insurance Co 53,800$3,440,5100.84%
HOHIMER WEALTH MANAGEMENT, LLC 47,352$3,028,1600.84%
LBP AM SA 549,389$35,133,4270.83%
Alta Wealth Advisors LLC 22,046$1,409,8500.83%
DELTA FINANCIAL ADVISORS LLC 29,275$1,872,1110.83%
TODD ASSET MANAGEMENT LLC 553,077$35,369,2740.82%
Adalta Capital Management LLC 19,227$1,2300.82%
Ceeto Capital Group, LLC 28,000$1,7910.82%
KINGSWOOD WEALTH ADVISORS, LLC 40,204$2,571,0990.82%
Farmers & Merchants Trust Co of Chambersburg PA 19,795$1,2660.82%
Redwood Wealth Management Group, LLC 11,516$736,4350.82%
Beaton Management Co. Inc. 20,158$1,2890.82%
Greystone Financial Group, LLC 54,916$3,511,8780.81%
Talbot Financial, LLC 74,685$4,776,1060.81%
SevenBridge Financial Group, LLC 49,112$3,140,6850.81%
BNP Paribas Asset Management Holding S.A. 4,083,001$261,1080.81%
Rosenbaum Jay D. 7,721$493,7580.79%
Caption Management, LLC 698,500$44,669,0750.79%
About BRISTOL MYERS SQUIBB CO

Bristol Myers Squibb Co. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that treat a wide range of diseases, including cancer, cardiovascular disease, and HIV/AIDS.

One of the company's most significant achievements is the development of Opdivo, a drug that has revolutionized the treatment of cancer. Opdivo is a checkpoint inhibitor that helps the immune system fight cancer cells. The drug has been approved for the treatment of several types of cancer, including melanoma, lung cancer, and renal cell carcinoma.

Bristol Myers Squibb Co. has also been at the forefront of the fight against HIV/AIDS. The company's drug, Reyataz, is a protease inhibitor that is used in combination with other drugs to treat HIV/AIDS. The drug has been instrumental in helping people with HIV/AIDS live longer, healthier lives.

The company's commitment to innovation and research has made it a leader in the pharmaceutical industry. Bristol Myers Squibb Co. has a strong pipeline of drugs in development, including treatments for cancer, cardiovascular disease, and immunology.

In conclusion, Bristol Myers Squibb Co. is a pharmaceutical company that has made significant contributions to the treatment of diseases such as cancer and HIV/AIDS. The company's commitment to innovation and research has made it a leader in the industry, and its pipeline of drugs in development promises to bring new treatments to patients in need.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BRISTOL MYERS SQUIBB CO's shareholders in Q2 2023. To view BRISTOL MYERS SQUIBB CO's shareholder history, click here.